Dexamethasone punctal plug - Ocular Therapeutix

Drug Profile

Dexamethasone punctal plug - Ocular Therapeutix

Alternative Names: Dexamethasone intracanalicular plug; Dexamethasone punctum plug; Dextenza; OTX-DP

Latest Information Update: 18 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ocular Therapeutix
  • Class Anti-inflammatories; Antiemetics; Antineoplastics; Fluorinated steroids; Glucocorticoids; Pregnadienetriols; Small molecules
  • Mechanism of Action Glucocorticoid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Ocular pain
  • Phase III Allergic conjunctivitis; Ocular inflammation
  • Phase II Dry eyes

Most Recent Events

  • 07 Nov 2017 Ocular Therapeutix announces intention to resubmit NDA to US FDA for Ocular pain in the first half of 2018
  • 12 Jul 2017 US FDA denies NDA of dexamethasone punctal plug for treatment of Ocular pain in USA
  • 11 Jul 2017 Ocular Therapeutics receives complete response letter from the FDA for Dexamethasone punctal plug in Ocular pain
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top